Free-text search
Articles per year:
Content Types
-
Pila Pharma cleared to begin obesity trial
Swedish–Danish Pila Pharma has received approval from the European Medicines Agency (EMA) to begin a clinical trial of the company’s drug candidate for obesity.
-
Life sciences fuel Greater Copenhagen's economic growth
The expansion of the life sciences sector on the Danish side of the Øresund is a key reason why the Danish-Swedish Greater Copenhagen region has emerged as one of Northern Europe's strongest growth hubs.
-
Sanofi cuts 229 jobs following $9.1bn acquisition
A new round of job cuts is hitting the US biotech hub of Massachusetts. Sanofi is cutting 229 positions and closing former Blueprint offices, while Merck KGaA is also reducing headcount in its US R&D operations.
-
Evaxion drops solid tumour vaccine to advance new glioblastoma program
Danish biotech company Evaxion is discontinuing a vaccine candidate for solid tumors and redirecting resources to a program specifically aimed at brain cancer.
-
CAR‑T developer Elicera appoints new CEO
Swedish CAR‑T developer Elicera has appointed Johan Liwing as its new CEO, succeeding Jamal El‑Mosleh, who is stepping down.
-
Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
Tobacco for cancer, heroin for coughs, mercury for teething babies. Humanity’s path towards today’s evidence‑based medicine has been lined with strange misjudgements, outright quackery and “cures” that often caused more harm than good.
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
Hacker group claims Chinese bid for stolen Novo data
Earlier this year, Novo Nordisk was hit by a high‑profile data breach in which a large amount of sensitive information was stolen. Now a hacker group claims that it was offered millions of dollars for the stolen data from a Chinese company – but instead published the information openly on the internet.
-
Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer
Eli Lilly has until now had the US market for tau PET imaging in Alzheimer’s disease to itself. The pharmaceutical giant is now facing competition after the FDA approved radiopharmaceutical company Lantheus Holdings’s Tauklarify.
-
AstraZeneca scraps late‑stage study – and reports dual successes in lung cancer
AstraZeneca is discontinuing a global Phase III trial that has been evaluating the antibody volrustimig for non‑small cell lung cancer after the chances of success were deemed low. At the same time, the company is reporting promising data for two other lung‑cancer candidates.
-
Life Science Nordic launches – bringing Nordic life science news under one roof
Welcome to Life Science Nordic – your source for the news and insights shaping the Nordic life science and medtech industries. We provide independent, in-depth journalism covering developments across the Nordic market.
-
Hansa chair: “Too many boards spend far too much time looking inwards”
Following a change of chief executive and a sharper strategic focus, Hansa Biopharma is entering a decisive phase in the US market. As the company prepares for what comes next, chair Peter Nicklin is clear about his own role: to lead the board, but never dominate it.
-
Gold Rush in Oral Peptides: “Everybody Wants In”
After Ozempic, pharmaceutical companies are racing toward the next big revolution: peptides that can be swallowed as easily as they can be injected. Cyprumed is building the technology to get them there.
-
EMA opens review of Europe’s first potential Lyme disease vaccine
The European Medicines Agency (EMA) has validated Valneva’s and Pfizer’s application for approval of the companies’ Lyme disease vaccine, meaning it is now ready for formal scientific review.
-
Tuff vecka för Fresenius Kabi – dubbla återkallanden
Fresenius Kabi återkallar ett parti av en av sina biosimilarer i USA sedan produkten visat sig innehålla glaspartiklar. Missen uppdagades bara en vecka efter att bolaget i ett annat ärende upptäckt felmärkta sprutor med ett särskilt starkt opioidläkemedel.
-
Ny finanschef till Biolamina
Biotechbolaget Biolamina, verksamt inom cellodling och stamcellsteknik, har rekryterat Sofia Helgesson som finanschef (CFO).
-
Thermo Fishers mikrobiologiverksamhet byter ägare
Thermo Fisher har nu genomfört försäljningen av sin mikrobiologienhet till ett privat riskkapitalbolag, som kommer att driva verksamheten vidare som ett självständigt bolag.
-
Phase III win for LSD‑based anxiety drug
An LSD‑based drug candidate for anxiety disorders is reported to show strong results in late‑stage clinical testing.
-
EU approves Rinvoq for severe patchy hair loss
AbbVie’s well‑known rheumatoid arthritis drug Rinvoq has now been approved in the EU for a completely different indication: severe alopecia areata, or patchy hair loss.
-
Lilly sues six companies over black market sales of experimental weight loss drug
Eli Lilly is suing six companies in the United States accused of selling illegal versions of the company’s upcoming triple‑acting weight‑loss drug, retatrutide.
-
Läkemedel mot reumatism får grönt ljus för håravfall
Abbvies välkända reumatismläkemedel Rinvoq har nu EU‑godkänts för en helt annan indikation: svår alopecia areata, eller fläckvis håravfall.
-
Low-profile Danish biotech recruits Mikael Dolsten
Danish biotech company Quantumcell has quietly assembled a heavyweight group of investors, including Novo Holdings and the Lundbeck Foundation. Following its multibillion-dollar deal with Sweden’s Alzecure, the company is now strengthening its ranks further – with Swedish executive Mikael Dolsten joining the board.
-
Framgång i fas III för LSD-baserad tablett mot ångest
En LSD‑baserad läkemedelskandidat mot ångestsyndrom rapporteras visa starka resultat i sen klinisk fas.
-
Dansk doldis värvar Mikael Dolsten
Det danska biotechbolaget Quantumcell har i det tysta byggt upp en tung ägarkrets med bland andra Novo Holdings och Lundbeckfonden. Efter miljardavtalet med svenska Alzecure förstärker bolaget nu ytterligare – med svenske Mikael Dolsten i styrelsen.
BREAKING